SANTA CRUZ BIOTECHNOLOGY, INC.

C4orf36 (L-14): sc-245763

BACKGROUND

C4orf36 (chromosome 4 open reading frame 36) is a 117 amino acid protein that is encoded by a gene mapping to human chromosome 4, which represents approximately 6% of the human genome and contains nearly 900 genes. Notably, the Huntingtin gene, which is found to encode an expanded glutamine tract in cases of Huntington's disease, is on chromosome 4. FGFR-3 is also encoded by a gene that maps to human chromosome 4 and has been associated with thanatophoric dwarfism, achondroplasia, Muenke syndrome and bladder cancer. Chromosome 4 is also tied to Ellis-van Creveld syndrome, methylmalonic acidemia and polycystic kidney disease.

REFERENCES

1. Hillier, L.W., et al. 2005. Generation and annotation of the DNA sequences of human chromosomes 2 and 4. Nature 434: 724-731.
2. Cowan, C.M. and Raymond, L.A. 2006. Selective neuronal degeneration in Huntington's disease. Curr. Top. Dev. Biol. 75:25-71.
3. Chandler, R.J., et al. 2007. Metabolic phenotype of methylmalonic acidemia in mice and humans: the role of skeletal muscle. BMC Med. Genet. 8: 64.
4. Cunningham, M.L., et al. 2007. Syndromic craniosynostosis: from history to hydrogen bonds. Orthod. Craniofac. Res. 10: 67-81.
5. de Frutos, C.A., et al. 2007. Snail1 is a transcriptional effector of FGFR3 signaling during chondrogenesis and achondroplasias. Dev. Cell 13: 872-883.
6. Versteegh, F.G., et al. 2007. Growth hormone analysis and treatment in Ellis-van Creveld syndrome. Am. J. Med. Genet. A 143A: 2113-2121.
7. Doherty, E.S., et al. 2007. Muenke syndrome (FGFR3-related craniosynostosis): Expansion of the phenotype and review of the literature. Am. J. Med. Genet. A 143A: 3204-3215.
8. Ruiz-Perez, V.L., et al. 2007. Evc is a positive mediator of Ihh-regulated bone growth that localises at the base of chondrocyte cilia. Development 134: 2903-2912.
9. Stack, E.C., et al. 2007. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. J. Neurosci. 27: 12908-12915.

CHROMOSOMAL LOCATION

Genetic locus: C4orf36 (human) mapping to 4q21.3.

SOURCE

C4orf36 (L-14) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of C4orf36 of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-245763 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

C4orf36 (L-14) is recommended for detection of C4orf36 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for C4orf36 siRNA (h): sc-89232, C4orf36 shRNA Plasmid (h): sc-89232-SH and C4orf36 shRNA (h) Lentiviral Particles: sc-89232-V.

Molecular Weight of C4orf36: 13 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.